Core Viewpoint - DaVita Inc. is a leading healthcare provider in kidney care services, facing challenges from rising costs and a recent ransomware attack, but has shown strong quarterly performance leading to a year-to-date stock increase of 24% [1][2]. Company Overview - DaVita Inc. specializes in kidney care services, including dialysis treatments for chronic kidney failure patients, and is headquartered in Denver, Colorado with a market capitalization of $9.94 billion [1]. Stock Performance - Over the past year, DaVita's stock has declined by 18.2%, but it has rebounded with a 24% increase year-to-date [2]. - The stock reached a 52-week low of $101 on January 14, but has since increased by 39.4% from that level [2]. - In comparison, the S&P 500 Index gained 14% over the same period, indicating underperformance relative to the broader market [3]. Financial Results - DaVita reported a 9.9% year-over-year increase in Q4 revenue to $3.62 billion, driven by a 9% growth in dialysis patient service revenues to $3.40 billion [3]. - The company anticipates headwinds due to the expiration of the Affordable Care Act, but expects to offset these challenges with the elimination of cyber-incident impacts in 2025 [3]. Earnings Projections - Analysts expect DaVita's EPS to increase by 20.5% year-over-year to $2.41 for the current quarter, with further annual increases projected to $14.16 in fiscal 2026 and $16.90 in fiscal 2027 [4]. Analyst Ratings - Among eight Wall Street analysts covering DaVita, the consensus rating is a "Hold," with two "Strong Buy" ratings, five "Holds," and one "Moderate Sell" [5]. - The ratings configuration has become slightly more bullish, with the number of "Strong Buy" ratings increasing from one to two [5].

Core Insights - FTI Consulting has appointed Mustapha Labassi as a Senior Managing Director in the Transaction Services practice within the Corporate Finance & Restructuring segment [1] Group 1: Appointment and Experience - Mr. Labassi has over 15 years of experience in the M&A life cycle, focusing on financial due diligence for both buy-side and sell-side transactions [2] - He has advised French private equity firms and large European corporations on domestic and cross-border deals across Europe and French-speaking African countries [2] - His sector expertise includes healthcare, technology, media, telecommunications, software, and business services [2] Group 2: Role and Strategic Importance - In his new role, Mr. Labassi will enhance FTI Consulting's financial due diligence and deal capabilities in France, advising clients on M&A transactions across various industries [3] - The appointment is part of FTI Consulting's strategy to strengthen its transactional expertise in key European markets, responding to client demand for meticulous due diligence and M&A advisory support [4][5] Group 3: Company Overview - FTI Consulting is a leading global expert firm with over 8,100 employees in 32 countries, generating $3.70 billion in revenues during fiscal year 2024 [6]

Industry Overview - Small-cap and penny stocks are experiencing a notable rally, with the Russell 2000 index up by over 5%, significantly outperforming the S&P 500, which is up by only 1.7% [1] - The rally is driven by expectations of market-beating results from these companies, which are trading at discounted valuations [1][2] - The Federal Reserve's anticipated monetary policy easing is further supporting the case for investing in penny and small-cap stocks [2] January Effect - The January effect is benefiting small-cap companies as investors are buying smaller stocks, particularly those that faced tax-loss selling in the previous quarter [3] - The Russell 2000 index has shown strong performance in January, suggesting potential continued strength into February [3] Fundamentals and Valuations - Fundamentals for small-cap companies are improving, with their 1-year price-to-earnings multiples being 30% lower than those of large-cap companies [4] - Small caps have shown earnings growth that slightly exceeded larger companies for the first time in thirteen quarters [4] Seasonal Trends - Historically, small caps perform better in midterm election years, averaging a 1.3% advance in February compared to the S&P 500's average of 0.3% [5] - Current seasonal patterns indicate a hawkish bias towards interest rates, favoring small-cap stocks [5] Investment Opportunities - The S&P SmallCap 600 index is already up by more than 5% for the year, indicating a favorable environment for investing in penny stocks trading under $5 [6] - A list of 14 NYSE penny stocks has been compiled based on popularity among hedge funds and potential upside of over 30% [8][9] Company Highlights - **Nouveau Monde Graphite Inc. (NYSE:NMG)**: Current share price is $2.09 with an upside potential of 107.33%. The company has a net asset value of $919 million or $3.51 per share, factoring in a cash balance of $68.8 million and debt of $11.6 million [11][12]. It has signed a 7-year off-take agreement with the Canadian government for 30,000 tons per annum of graphite concentrate [13][14]. - **Auna SA (NYSE:AUNA)**: Current share price is $4.76 with an upside potential of 53.36%. Analysts expect significant growth due to a $500 million expansion in Mexico and a strategic partnership with Sojitz [15][16][17]. The company operates a vertically integrated network of healthcare facilities in Latin America, focusing on high-complexity care [18].

Core Viewpoint - Berkshire Hathaway has two strong investment opportunities in DaVita and Kraft Heinz, while UnitedHealthcare Group is currently not recommended for investment. Group 1: DaVita (DVA) - DaVita has been a long-term investment for Berkshire Hathaway since 2011 and is showing signs of recovery after beating quarterly expectations and providing optimistic 2026 earnings guidance [5][7]. - The current stock price of DaVita is $140.71, with a market cap of $9.9 billion and a gross margin of 27% [6][7]. - DaVita's earnings per share for the year are expected to be between $13.60 and $15, suggesting it is trading at a low multiple of around 9 times forward earnings, compared to its historical range of 13 to 14 times [8]. Group 2: Kraft Heinz (KHC) - Berkshire Hathaway holds a 27% stake in Kraft Heinz, valued at approximately $7.5 billion, but has faced significant losses on this investment and may consider selling part of its stake [9][10]. - Kraft Heinz is currently trading at about 9 times forward earnings, which is a discount compared to its peers, presenting a potential opportunity for new investors [11]. - The company plans to split into two entities to unlock value, similar to Kellogg's successful separation in 2023, which could enhance shareholder value [12]. Group 3: UnitedHealthcare Group (UNH) - Berkshire Hathaway purchased 5 million shares of UnitedHealthcare Group, but the stock has faced challenges due to lower-than-expected Medicare Advantage payment increases, leading to a drop in stock price from $350 to around $280 [13][14]. - UnitedHealthcare currently trades at 16 times forward earnings, which is a premium compared to peers, indicating potential for further multiple compression as the company's growth narrative is under pressure [15].

Core Viewpoint - McKesson Corporation (NYSE:MCK) is highlighted as a significant player in the healthcare services sector, with strong stock performance and positive analyst outlooks, despite some market challenges [2][3]. Company Performance - McKesson's shares have increased by 59% over the past year and by 15% year-to-date [2]. - TD Cowen raised the share price target to $1,012 from $1,000 while maintaining a Buy rating, citing strong performance in the pharmaceutical and cancer businesses [2]. - Morgan Stanley also raised its price target to $966 from $916, keeping an Overweight rating, with optimism driven by the cancer business [2]. Market Context - The company is noted for its significant role in the healthcare industry, being one of the largest providers in America [2]. - Jim Cramer has recently discussed McKesson in the context of its influence and market position, even comparing its power to that of President Trump [3].

Group 1 - Morgan Stanley raised the price target on Cardinal Health (CAH) to $255 from $245 [1] - The firm maintains an Overweight rating on Cardinal Health shares [1] - The updated risk-reward profile follows the company's strong Q2 results [1]

Core Viewpoint - Omnicell, Inc. has set a new price target of $49, indicating a potential upside despite recent challenges in earnings performance [1][6] Financial Performance - The stock price dropped significantly from a previous close of $46.69 to a last traded price of $38.38 following a disappointing earnings announcement [2] - Omnicell reported earnings per share (EPS) of $0.40, missing the consensus estimate of $0.47 by $0.07 [2] - Revenue for the quarter was $313.98 million, slightly exceeding analysts' expectations of $313.36 million, representing a 2.3% increase year-over-year [3] Guidance and Outlook - The company has raised its guidance for Q1 2026 to an EPS range of $0.26 to $0.36 and for FY 2026 to an EPS range of $1.65 to $1.85, indicating a positive outlook [4][6] - Despite a 16.30% decrease in stock price on the day of the earnings announcement, the new price target suggests potential growth for Omnicell [4][5] Market Position - Omnicell operates in a competitive market with key players such as McKesson and Cardinal Health [1] - The company's market capitalization is approximately $1.80 billion, with a trading volume of 2,835,483 shares [5]

Core Insights - Molina Healthcare, Inc. reported a fourth-quarter 2025 adjusted loss of $2.75 per share, significantly missing the Zacks Consensus Estimate of an adjusted EPS of 43 cents, compared to an EPS of $5.05 in the prior-year quarter [1][9] - Revenues for the quarter reached $11.4 billion, reflecting an 8.3% year-over-year increase and surpassing the consensus estimate by 5.3% [1][5] Financial Performance - For the full year 2025, Molina reported total revenues of $45.4 billion, up from $40.7 billion in 2024, exceeding the consensus estimate of $44.8 billion [5] - Adjusted EPS for 2025 declined to $11.03 from $22.65 in 2024 but still beat the consensus estimate of $10.65 [5] - Adjusted net income fell to $584 million from $1.3 billion a year ago [5] Operational Highlights - Premium revenues in Q4 totaled $10.7 billion, a 7.3% year-over-year increase, exceeding both the Zacks Consensus Estimate and internal estimates [6] - Total membership as of December 31, 2025, declined by 0.8% year over year to approximately 5.49 million, missing the Zacks Consensus Estimate of 5.52 million [6] - The medical care ratio (MCR) increased by 440 basis points year over year to 94.6%, exceeding both the consensus estimate and internal estimates [8] Expense and Income Analysis - Investment income decreased by 11.7% year over year to $98 million, below the consensus estimate of $100.1 million [7] - Total operating expenses rose by 14% year over year to $11.5 billion, exceeding internal estimates, primarily due to higher medical care costs and increased general and administrative expenses [7][8] - Interest expense grew by 52.9% year over year to $52 million [8] Future Guidance - For 2026, management expects premium revenues to decline by 2% year over year to $42.2 billion, with adjusted earnings projected to be at least $5.00 per share [12] - Adjusted net income is anticipated to be $256 million, with total membership estimated to decrease to 5.1 million by the end of 2026 [13]

Core Insights - Cardinal Health reported strong fiscal second-quarter 2026 results, with total revenue of $66 billion, up 19% year over year, driven by robust demand in Pharmaceutical and Specialty Solutions [3][4] - Operating earnings reached $877 million, a 38% increase from the prior year, while non-GAAP diluted EPS rose 36% to $2.63 [1][6] - The company raised its full-year earnings guidance, expecting non-GAAP diluted EPS to be between $10.15 and $10.35, indicating a year-over-year growth of 23% to 26% [17] Financial Performance - Gross margin dollars increased by 24% to $2.4 billion, attributed to a favorable mix, while SG&A expenses rose 16% to $1.5 billion [2] - The effective tax rate remained flat at 21.4%, with a lowered outlook for the effective tax rate to 21% to 23% for the full year [1][18] - Cardinal Health generated $1.8 billion in adjusted free cash flow year to date and ended the quarter with $2.8 billion in cash [19] Segment Performance - Pharmaceutical and Specialty Solutions revenue increased by 19% to $61 billion, with segment profit rising 29% to $687 million [6][7] - The Global Medical Products and Distribution (GMPD) segment saw revenue growth of 3% to $3.3 billion, with segment profit improving to $37 million from $18 million a year ago [10][11] - Other businesses, including Nuclear and Precision Health Solutions, at-Home Solutions, and OptiFreight Logistics, reported revenue growth of 34% to $1.7 billion and segment profit growth of 52% to $179 million [13] Strategic Focus - Management emphasized that specialty remains a strategic priority, with expectations for specialty revenues to surpass $50 billion in fiscal 2026 [8][6] - The company is investing in its distribution footprint and technology, achieving a 10% improvement in service levels over the past two years [8] - Cardinal Health's M&A activities are expected to contribute about 8% to total growth in the pharmaceutical business for the full year [9] Guidance and Outlook - The company updated its revenue guidance for the Pharma segment, maintaining expectations while raising segment profit growth outlook to 20% to 22% [22] - GMPD revenue outlook was adjusted to 1% to 3% growth, with segment profit guidance raised to approximately $150 million [22] - Other businesses maintained revenue guidance at 26% to 28% growth, with segment profit growth outlook raised to 33% to 35% [22]

Core Insights - Encompass Health reported revenue of $1.54 billion for the quarter ended December 2025, reflecting a year-over-year increase of 9.9% [1] - The earnings per share (EPS) for the quarter was $1.46, up from $1.17 in the same quarter last year, indicating a significant improvement [1] - The revenue exceeded the Zacks Consensus Estimate by 0.23%, while the EPS surpassed the consensus estimate by 12.95% [1] Financial Performance Metrics - Net patient revenue per discharge was reported at $22,273, which was higher than the estimated $22,062.08 [4] - The total number of discharges was 67,238, slightly below the estimated 67,407 [4] - Net Operating Revenues from inpatient services reached $1.5 billion, exceeding the estimated $1.49 billion, marking a 9.6% increase compared to the previous year [4] Stock Performance - Encompass Health's shares have declined by 10.1% over the past month, contrasting with a 0.5% increase in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]